COGENT BIOSCIENCES INC (COGT) Stock Price, Quote, News and Overview
NASDAQ:COGT - Nasdaq - US19240Q2012 - Common Stock - Currency: USD
COGT Quote, Performance and Key Statistics
5.87
+0.24 (+4.26%)
The current stock price of COGT is 5.87 USD. In the past month the price increased by 10.13%. In the past year, price decreased by -22.05%.
COGT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.33 | 351.09B | ||
| AMGN | AMGEN INC | 13.55 | 151.20B | ||
| GILD | GILEAD SCIENCES INC | 13.4 | 129.08B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1728.1 | 128.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.67 | 65.39B | ||
| ARGX | ARGENX SE - ADR | 341.93 | 39.67B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.74B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.57B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.23B | ||
| NTRA | NATERA INC | N/A | 21.30B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.72B | ||
| BIIB | BIOGEN INC | 7.81 | 18.10B |
Related stock screener links
About COGT
Company Profile
Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. The company is headquartered in Waltham, Massachusetts and currently employs 205 full-time employees. The company went IPO on 2018-03-29. The firm is focused on developing precision therapies for genetically defined diseases. The Company’s clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3Kα. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.
Company Info
COGENT BIOSCIENCES INC
275 Wyman Street, 3rd Floor
Waltham MASSACHUSETTS 02140 US
CEO: Andrew Robbins
Employees: 164
Phone: 16179455576
COGENT BIOSCIENCES INC / COGT FAQ
What is the stock price of COGENT BIOSCIENCES INC today?
The current stock price of COGT is 5.87 USD. The price increased by 4.26% in the last trading session.
What is the ticker symbol for COGENT BIOSCIENCES INC stock?
The exchange symbol of COGENT BIOSCIENCES INC is COGT and it is listed on the Nasdaq exchange.
On which exchange is COGT stock listed?
COGT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for COGENT BIOSCIENCES INC stock?
18 analysts have analysed COGT and the average price target is 16.42 USD. This implies a price increase of 179.76% is expected in the next year compared to the current price of 5.87. Check the COGENT BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is COGENT BIOSCIENCES INC worth?
COGENT BIOSCIENCES INC (COGT) has a market capitalization of 668.30M USD. This makes COGT a Small Cap stock.
How many employees does COGENT BIOSCIENCES INC have?
COGENT BIOSCIENCES INC (COGT) currently has 164 employees.
What are the support and resistance levels for COGENT BIOSCIENCES INC (COGT) stock?
COGENT BIOSCIENCES INC (COGT) has a support level at 4.38 and a resistance level at 6.84. Check the full technical report for a detailed analysis of COGT support and resistance levels.
Should I buy COGENT BIOSCIENCES INC (COGT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of COGT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of COGT, evaluating the profitability, health, valuation and growth aspects
- COGENT BIOSCIENCES INC (COGT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- COGENT BIOSCIENCES INC (COGT) Sales and EPS estimates to see what analysts future expectations are.
- COGENT BIOSCIENCES INC (COGT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- COGENT BIOSCIENCES INC (COGT) Insider and Institutional Ownership to learn about the owners and their transactions.
- COGENT BIOSCIENCES INC (COGT) Stock Chart to make your own analysis
- COGENT BIOSCIENCES INC (COGT) Latest news and press-releases to stay up to date.
Does COGENT BIOSCIENCES INC (COGT) stock pay dividends?
COGT does not pay a dividend.
When does COGENT BIOSCIENCES INC (COGT) report earnings?
COGENT BIOSCIENCES INC (COGT) will report earnings on 2025-05-13, before the market open.
What is the Price/Earnings (PE) ratio of COGENT BIOSCIENCES INC (COGT)?
COGENT BIOSCIENCES INC (COGT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.97).
What is the Short Interest ratio of COGENT BIOSCIENCES INC (COGT) stock?
The outstanding short interest for COGENT BIOSCIENCES INC (COGT) is 12.71% of its float. Check the ownership tab for more information on the COGT short interest.
COGT Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to COGT. When comparing the yearly performance of all stocks, COGT is a bad performer in the overall market: 84.72% of all stocks are doing better.
COGT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to COGT. COGT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
COGT Financial Highlights
Over the last trailing twelve months COGT reported a non-GAAP Earnings per Share(EPS) of -1.97. The EPS increased by 17.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -61.43% | ||
| ROE | -78.59% | ||
| Debt/Equity | 0 |
COGT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to COGT. The Buy consensus is the average rating of analysts ratings from 18 analysts.